viewTetra Bio-Pharma

Tetra Bio-Pharma strengthens executive team with a series of new appointments

The firm is adding Dale Weil and Brent Norton to its board of directors and is welcoming Graham Wood as its new chief operating officer

Tetra Bio-Pharma -
Tetra is advancing a US FDA and a Health Canada-approved clinical program aimed at bringing novel prescription drugs and treatments to patients

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) announced a series of appointments on Thursday designed to strengthen the CBD drug discovery company’s executive team.

The Ottawa-based firm has named Graham Wood as its new chief operating officer, replacing Steeve Neron, who is transitioning into the chief commercial officer role.

In addition, the company is adding two seasoned healthcare executives to its board of directors in the form of former McKesson Canada senior advisor Dale Weil and Brent Norton, a medical doctor and venture partner with Lumira Ventures.

READ: Tetra Bio-Pharma taps clinical research veteran Jean-Francois Boily to CFO position

"We are pleased to welcome Dale and Brent to the Tetra Board and Graham to our executive team,” Tetra Bio-Pharma chairman Bill Cheliak said in a statement on the appointments.

“Guy and I feel confident that we have selected two highly qualified board members who will bring additional knowledge, talent, experiences, and perspective to the Board. Their leadership and commitment will be invaluable as we advance many of our clinical assets to commercialization.”

New COO Graham Wood holds a PhD from McGill University and spent over 21 years in the pharmaceutical industry, developing an expertise in inhalation clinical research. Wood spent five years at leading clinical research facility Altasciences, where he conducted over 40 studies on different cannabinoid products including Tetra’s own QIXLEEF.

Tetra CEO Guy Chamberland told investors the new COO will be actively involved in the firm’s inhalation programs: “(Wood) will support Tetra's clinical team and be backed by our highly experienced pharmaceutical compliance unit.”

Chamberland said. “The addition of Graham will provide me and the Board with the oversight required to manage our clinical program."

Tetra is advancing a US Foord & Drug Administration and a Health Canada-approved cannabinoid-based clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Tetra Bio-Pharma

Price: - -

Market: TSX-V
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tetra Bio-Pharma named herein, including the promotion by the Company of Tetra Bio-Pharma in any Content on the Site, the Company receives from...


Tetra Bio-Pharma acquires Canadian rights to Dronabinol Soft Gel capsules,...

Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB:TBPMF) Chief Commercial Officer Steeve Néron tells Proactive the biotech has acquired the Canadian exclusive rights for Dronabinol Soft Gel capsules, cannabinoid derived prescription drug aimed to treat AIDS-related anorexia and severe nausea and vomiting...

3 weeks, 1 day ago

2 min read